[Chronic granulomatous disease: pathogenesis and therapy of associated fungal infections]

Med Sci (Paris). 2012 Nov;28(11):963-9. doi: 10.1051/medsci/20122811015. Epub 2012 Nov 12.
[Article in French]

Abstract

Chronic granulomatous disease is a genetic disorder responsible for a defect in the NADPH oxidase of phagocytic cells. It impairs the oxidative burst necessary to the intracellular inactivation of microorganisms and predisposes to an increased risk of infections by various microorganisms, including fungi like Aspergillus spp. and other less frequently encountered or emerging fungal species. Here we review the genetic basis, pathogenesis and clinical presentation associated with fungal infections in chronic granulomatous disease as well as the current prophylaxis and newly available therapies.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / etiology
  • Aspergillosis / immunology
  • Aspergillosis / therapy
  • Disease Susceptibility
  • Genetic Therapy
  • Granulomatous Disease, Chronic / complications*
  • Granulomatous Disease, Chronic / enzymology
  • Granulomatous Disease, Chronic / epidemiology
  • Granulomatous Disease, Chronic / immunology
  • Granulomatous Disease, Chronic / surgery
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunocompromised Host
  • Incidence
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / metabolism
  • Lymphocyte Subsets / immunology
  • Mice
  • Mycoses / epidemiology
  • Mycoses / etiology*
  • Mycoses / immunology
  • Mycoses / prevention & control
  • Mycoses / therapy
  • NADPH Oxidases / deficiency
  • NADPH Oxidases / genetics
  • NADPH Oxidases / physiology
  • Neutrophils / enzymology
  • Neutrophils / immunology
  • Protein Subunits
  • Respiratory Burst
  • Tryptophan / metabolism

Substances

  • Anti-Inflammatory Agents
  • Antifungal Agents
  • Indoleamine-Pyrrole 2,3,-Dioxygenase
  • Protein Subunits
  • Tryptophan
  • NADPH Oxidases